# Kazia Therapeutics Ltd: overview KZIA · Nasdaq · CIK 1075880 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Jun 30 Pages: [Overview](/companies/kzia.md) · [Financials](/companies/kzia/financials.md) · [Filings](/companies/kzia/filings.md) · [Insiders](/companies/kzia/insiders.md) Revenue is not reported in this company’s XBRL financial statements. ## Last eight quarters Not reported. ## Last five fiscal years | Line item | Unit | FY2021 (2021-06-30) | FY2022 (2022-06-30) | FY2023 (2023-06-30) | FY2024 (2024-06-30) | FY2025 (2025-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [15.2](/filings/0001193125-23-263551.md) | [0.0](/filings/0001193125-24-259805.md) | [0.0](/filings/0001193125-25-272284.md) | [2.3](/filings/0001193125-25-272284.md) | [0.0](/filings/0001193125-25-272284.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | | Net margin | % | [(55.5%)](/filings/0001193125-23-263551.md) | not reported | not reported | [(1160.2%)](/filings/0001193125-25-272284.md) | [(49290.5%)](/filings/0001193125-25-272284.md) | | Diluted EPS | $ per share | [(0.07)](/filings/0001193125-23-263551.md) | [(0.19)](/filings/0001193125-24-259805.md) | [(0.11)](/filings/0001193125-25-272284.md) | [(0.10)](/filings/0001193125-25-272284.md) | [(0.04)](/filings/0001193125-25-272284.md) | | Free cash flow | $m | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL Revenue: ifrs-full:RevenueFromContractsWithCustomers; Revenue: ifrs-full:Revenue. - Gross margin (gross profit / revenue). XBRL Revenue: ifrs-full:RevenueFromContractsWithCustomers; Revenue: ifrs-full:Revenue. - Operating margin (operating income / revenue). XBRL Revenue: ifrs-full:RevenueFromContractsWithCustomers; Revenue: ifrs-full:Revenue. - Net margin (net income / revenue). XBRL Net income: ifrs-full:ProfitLossAttributableToOwnersOfParent; Revenue: ifrs-full:RevenueFromContractsWithCustomers; Revenue: ifrs-full:Revenue. - Diluted EPS. XBRL Diluted EPS: ifrs-full:DilutedEarningsLossPerShare. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: ifrs-full:CashFlowsFromUsedInOperatingActivities. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/kzia/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Boxer Capital Management, LLC](/funds/2018299.md) | 2026-06-30 | $7.9m | 560,000 | | New +560,000 | | [FLPUTNAM INVESTMENT MANAGEMENT CO](/funds/1140334.md) | 2026-06-30 | $5.8m | 414,958 | | Added +272,489 | | [Bleichroeder LP](/funds/1781002.md) | 2026-06-30 | $5.6m | 400,000 | | Unchanged | | [Ikarian Capital, LLC](/funds/1778253.md) | 2026-06-30 | $5.6m | 396,201 | | New +396,201 | | [Dauntless Investment Group, LLC](/funds/2044285.md) | 2026-06-30 | $5.0m | 354,208 | | Added +274,376 | | [Stonepine Capital Management, LLC](/funds/1440771.md) | 2026-06-30 | $4.9m | 345,179 | | Unchanged | | [SUSQUEHANNA INTERNATIONAL GROUP, LLP](/funds/1446194.md) | 2026-06-30 | $3.5m | 251,700 | Call | New +251,700 | | [Point72 Asset Management, L.P.](/funds/1603466.md) | 2026-06-30 | $2.3m | 200,300 | | Added +300 | | [Ensign Peak Advisors, Inc](/funds/1454984.md) | 2026-06-30 | $1.6m | 110,778 | | New +110,778 | | [MILLENNIUM MANAGEMENT LLC](/funds/1273087.md) | 2026-06-30 | $1.4m | 101,376 | | New +101,376 | ## Recent filings [All 912 filings](/companies/kzia/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-09-22 | 12:00 ET | [6-K](/filings/0001213900-26-101967.md) | Report of a foreign private issuer, period 2026-09-22 | 0001213900-26-101967 | | 2026-09-18 | 20:01 ET | [6-K](/filings/0001213900-26-101400.md) | Report of a foreign private issuer, period 2026-09-18 | 0001213900-26-101400 | | 2026-09-01 | 20:55 ET | [6-K](/filings/0001213900-26-096263.md) | Report of a foreign private issuer, period 2026-09-01 | 0001213900-26-096263 | | 2026-08-31 | 11:30 ET | [6-K](/filings/0001213900-26-095348.md) | Report of a foreign private issuer, period 2026-08-31 | 0001213900-26-095348 | | 2026-08-31 | 10:14 ET | [6-K](/filings/0001213900-26-095310.md) | Report of a foreign private issuer, period 2026-08-31 | 0001213900-26-095310 | | 2026-08-28 | 10:10 ET | [6-K](/filings/0001213900-26-094603.md) | Report of a foreign private issuer, period 2026-08-28 | 0001213900-26-094603 | | 2026-08-27 | 20:37 ET | [6-K](/filings/0001213900-26-094408.md) | Report of a foreign private issuer, period 2026-08-27 | 0001213900-26-094408 | | 2026-07-28 | 11:30 ET | [6-K](/filings/0001213900-26-081982.md) | Report of a foreign private issuer, period 2026-07-28 | 0001213900-26-081982 | | 2026-06-02 | 13:00 ET | [6-K](/filings/0001213900-26-063820.md) | Report of a foreign private issuer, period 2026-06-02 | 0001213900-26-063820 | | 2026-05-26 | 12:00 ET | [6-K](/filings/0001213900-26-060779.md) | Report of a foreign private issuer, period 2026-05-26 | 0001213900-26-060779 | ## Latest annual report [Form 20-F for the fiscal year ended Jun 30, 2025](/filings/0001193125-25-272284.md), filed Nov 7, 2025. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1075880 - Tickers: KZIA - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: C3 - Filer category: Non-accelerated filer Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:32 ET. No prices; not investment advice.